Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Etivelcabtagene erigedleucel - Cellectis

Next Previous
Drug Profile

Etivelcabtagene erigedleucel - Cellectis

Alternative Names: eti-cel; UCART 20x22; UCART20x22 - Cellectis; UCART20x22 cell therapy; Universal chimeric antigen receptors 20x22 T-cell therapy - Cellectis

Latest Information Update: 19 Jan 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cellectis
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Non-Hodgkin's lymphoma
  • Preclinical Precursor B-cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 09 Dec 2023 Pharmacodynamics, efficacy and adverse events data from the phase I/IIa NatHaLi-01 trial in Non-Hodgkin's lymphoma presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
  • 02 Nov 2023 Efficacy and adverse events data from the NatHaLi-01 phase-I/II trial in Non-Hodgkin's lymphoma released by Cellectis
  • 05 Jun 2023 Pharmacodynamics data from preclinical trials in Non-Hodgkin's lymphoma released by Cellectis

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top